Interferon May Prevent HIV Viral Rebound After HAART Interruption in HIV Patients

Ferdinando Dianzani; Gabriella Rozera; Isabella Abbate; Gianpiero D'Offizi; Amina Abdeddaim; Chrysoula Vlassi; Giorgio Antonucci; Pasquale Narciso; Federico Martini; Maria R. Capobianchi

doi:10.1089/jir.2007.0076

Interferon May Prevent HIV Viral Rebound After HAART Interruption in HIV Patients

Journal of Interferon & Cytokine Research ◽

10.1089/jir.2007.0076 ◽

2008 ◽

Vol 28 (1) ◽

pp. 1-3 ◽

Cited By ~ 19

Author(s):

Ferdinando Dianzani ◽

Gabriella Rozera ◽

Isabella Abbate ◽

Gianpiero D'Offizi ◽

Amina Abdeddaim ◽

...

Keyword(s):

Viral Rebound ◽

Hiv Patients ◽

Haart Interruption

Download Full-text

Modeling Viral Suppression, Viral Rebound and State-Specific Duration of HIV Patients with CD4 Count Adjustment: Parametric Multistate Frailty Model Approach

Infectious Diseases and Therapy ◽

10.1007/s40121-020-00296-4 ◽

2020 ◽

Vol 9 (2) ◽

pp. 367-388 ◽

Cited By ~ 2

Author(s):

Zelalem G. Dessie ◽

Temesgen Zewotir ◽

Henry Mwambi ◽

Delia North

Keyword(s):

Viral Suppression ◽

Frailty Model ◽

Cd4 Count ◽

Viral Rebound ◽

Hiv Patients ◽

Model Approach

Download Full-text

Factors Associated With Viral Suppression and Rebound Among HIV Patients On Treatment: A Retrospective Study in Ghana

10.21203/rs.3.rs-996319/v1 ◽

2021 ◽

Author(s):

Stephen Opoku ◽

Samuel Asamoah Sakyi ◽

Nana Kwame Ayisi-Boateng ◽

Anthony Kwame Enimil ◽

Ebenezer Senu ◽

...

Keyword(s):

Viral Load ◽

Retrospective Study ◽

Viral Suppression ◽

Baseline Viral Load ◽

Clinical Staging ◽

Viral Rebound ◽

Duration Of Treatment ◽

Combination Drug ◽

Hiv Patients ◽

Factors Associated

Abstract Background Viral suppression remains the most desired outcome in the management of patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and this can be achieved by an effective combined Antiretroviral Therapy (cART). However, some patients who achieve viral suppression may experience viral rebound with dire consequence. We evaluated viral suppression and rebound and their associated factors among adult patients on cART in Kumasi, Ghana. Methods This hospital-based retrospective study was conducted at the Komfo Anokye Teaching Hospital in Ghana. We reviewed the medical records of 720 HIV patients on cART. Statistical analyses were performed using SPSS Version 26.0 and GraphPad prism version 8.0. P<0.05 was considered statistically significant. Results Proportions of patients with viral suppression and viral rebound were 76.1% and 21.0% respectively. Being diagnosed at WHO stage I [aOR=4.26, 95%CI (4.20-48.44), p<0.0001], having good adherence to ART [aOR=5.64, 95%CI (2.86-11.13), p<0.0001], taking Nevirapine-based regimen [aOR=4.66, 95%CI (1.20-18.04), p=0.0260] and increasing duration of treatment (p<0.0001) were independently associated with higher odds of viral suppression. However, being diagnosed at WHO stage II (aOR=7.39, 95%CI: 2.67-20.51; p<0.0001) and stage III (aOR=8.62, 95%CI: 3.16-23.50; p<0.0001), having poor adherence (aOR=175.48, 95%CI: 44.30-695.07; p<0.0001), recording baseline suppression value of 20-49 copies/mL (aOR=6.43, 95%CI: 2.72-15.17; p<0.0001) and being treated with Zidovudine/Lamivudine/Efavirenz (aOR=6.49, 95%CI: 1.85-22.79; p=0.004) and Zidovudine/Lamivudine/Nevirapine (aOR=18.68, 95% CI: 1.58-220.90; p=0.02) were independently associated with higher odds of viral rebound. Conclusion Approximately 76% viral suppression rate among HIV patients on cART in Kumasi falls below the WHO 95% target by the year 2030. Choice of ART combination, drug adherence, WHO clinical staging and baseline viral load are factors associated with suppression or rebound. These clinical characteristics of HIV patients must be monitored concurrently with the viral load.

Download Full-text